** U.S.-listed shares of Danish drugmaker Novo Nordisk NOVOb.CO, NVO.N down 3.8% at $63.37 premarket
** NVO says Lars Fruergaard Jørgensen is stepping down as CEO, but will stay on for a while to ensure a smooth transition
** Co is looking for a new CEO to replace him, and an announcement will be made soon
** Co says the change in leadership is due to "recent market challenges" and share price decline since mid-2024
** Jørgensen has been with Novo since 1991 and became CEO in 2017
** As of last close, NVO down 23% YTD
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.